You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
信达生物(01801.HK):达伯舒二线治疗第三期临床达到主要研究终点
阿思达克 04-13 15:18
信达生物(01801.HK)与礼来制药(LLY.US)於美国癌症研究协会2021年年会上,公布ORIENT-3的第三期临床研究结果。

ORIENT-3是一项研究「达伯舒」信迪利单抗对比多西他赛,用於晚期鳞状非小细胞肺癌(sqNSCLC)二线治疗的第三期临床研究。研究共入组290例一线含铂化疗治疗失败的受试者,结果显示,基於剔除多西他赛组在疾病进展之前即接受免疫治疗的患者主要分析人群(280例患者),达伯舒对比多西他赛显着延长总生存期(OS),达到主要研究终点。

信达生物医学科学与战略肿瘤部副总裁周辉表示,达伯舒是首个列入国家医保目录的抗PD-1单克隆抗体药物,作为二线单药治疗显着改善晚期鳞状NSCLC患者生存获益,期待该适应症可以尽快获批,以惠及更多患者。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account